… clarified the pathogenesis, at the molecular level, of thyroid carcinomas and … BRAF
V600E-mutated PTC [26] (Table 1). The association of BRAF mutation and PTC at advanced clinical …

… about the molecular pathogenesis of thyroid cancer, efforts … More than 98% of all BRAF
mutation found in thyroid tumor … outcome along with its clinic pathological correlation was not …

… pathogenesis and poorer clinicopathological outcomes in patients with PTC (20). In thyroid
cancer, the B-RafV600E mutation … , the association between B-Raf mutations and PTC clinical …

… abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to … Clinical and
histopathological profile of BRAF V600E mutation in conventional papillary thyroid carcinoma …

… clinical studies have demonstrated an association of BRAF … significance of BRAF V600E
mutation in the pathogenesis of … a high prevalence of BRAF V600E mutation in thyroid cancer. …

… Mutated BRAF PTC has been related to different clinical-… pathways implicated in the
pathogenetic process of aggressive TC. … BRAF mutation in papillary thyroid carcinoma: predictive …

… of papillary thyroid carcinoma (FVPTC) has an indolent clinical … by the absence of the BRAF
V600E mutation [17], whereas ~30… Pathogenic variants were defined as known pathogenic …

… in the pathogenesis of thyroid cancer. As a multi-kinase inhibitor, sorafenib potentially inhibits
… Clinically, BRAF V600E -mutated thyroid cancer cells exhibit primary resistance or poor …

… The extent to which routine genomic sequencing can identify relevant secondary genomic
alterations among BRAF V600E -mutant papillary thyroid carcinoma (PTC) is unknown. Such …

… BRAF is a potential molecular target in PTC, it is important to clarify the frequency and
clinical significance of BRAF mutation … Clinically, our institution prefers to carry out active …